BioSpace News Archive

Bionomics Limited announced that it will be participating in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in San Francisco on October 6-7, 2022.

Saol Therapeutics announced that the pivotal Phase 3 clinical trial evaluating Sodium Dichloroacetate for the treatment of a rare, pediatric, ultra-orphan mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency has achieved its targeted enrollment.

ViewRay, Inc. announced that San Pietro Fatebenefratelli Hospital in Rome has treated its 1,000th patient with MRIdian® MRI-guided radiation therapy.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced participation in the following scientific and industry conferences in October:

Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced the appointment of Keith Baker as the Company’s new Chief Financial Officer.

ChromaDex Corp. announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of the American College of Cardiology : Basic to Translational Science by a team of scientists led by Dr. Kevin O’Brien, Division of Cardiology, Department of Medicine, in collaboration with Dr. Rong Tian, Mitochondria and Metabolism Center, Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, Washington, USA.

Haemonetics Corporation, a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022.

Pfizer Inc. announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA®, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI® compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.

Talaris Therapeutics, Inc. today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California.

Clearside Biomedical, Inc. announced today that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world’s largest association of eye physicians and surgeons.